# Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer

> **NCT00536939** · PHASE2 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 2 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Enzastaurin
- **DRUG:** Bevacizumab
- **DRUG:** Paclitaxel
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00536939
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-11
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Study has been terminated due to slow enrollment
- **Last updated:** 2020-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00536939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00536939, "Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00536939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*